1.41 USD
-0.03 (-2.08%)
1.3803 USD
-0.03 (-2.11%)
We assign a fundamental rating of 4 out of 10 to LUCY. LUCY was compared to 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for LUCY as it has an excellent financial health rating, but there are worries on the profitability. LUCY is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
LUCY had negative earnings in the past year.
In the past year LUCY has reported a negative cash flow from operations.
In the past 5 years LUCY always reported negative net income.
LUCY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LUCY's Return On Assets of -70.22% is on the low side compared to the rest of the industry. LUCY is outperformed by 73.26% of its industry peers.
LUCY has a Return On Equity (-76.56%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.22% | ||
| ROE | -76.56% | ||
| ROIC | N/A |
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LUCY's Gross Margin of 22.83% is on the low side compared to the rest of the industry. LUCY is outperformed by 80.21% of its industry peers.
LUCY's Gross Margin has declined in the last couple of years.
LUCY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
LUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUCY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LUCY has been reduced compared to 5 years ago.
LUCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.08, we must say that LUCY is in the distress zone and has some risk of bankruptcy.
LUCY has a Altman-Z score of -0.08. This is comparable to the rest of the industry: LUCY outperforms 44.38% of its industry peers.
There is no outstanding debt for LUCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.08 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
A Current Ratio of 11.98 indicates that LUCY has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.98, LUCY belongs to the best of the industry, outperforming 94.65% of the companies in the same industry.
A Quick Ratio of 10.13 indicates that LUCY has no problem at all paying its short term obligations.
LUCY has a better Quick ratio (10.13) than 94.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.98 | ||
| Quick Ratio | 10.13 |
3. Growth
3.1 Past
LUCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.66%, which is quite impressive.
The Revenue has grown by 53.21% in the past year. This is a very strong growth!
The Revenue has been growing by 33.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)72.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.62%
Revenue 1Y (TTM)53.21%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%163.46%
3.2 Future
Based on estimates for the next years, LUCY will show a very strong growth in Earnings Per Share. The EPS will grow by 36.67% on average per year.
The Revenue is expected to grow by 117.64% on average over the next years. This is a very strong growth
EPS Next Y71.92%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year52.63%
Revenue Next 2Y117.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LUCY. In the last year negative earnings were reported.
Also next year LUCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LUCY's earnings are expected to grow with 36.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A
5. Dividend
5.1 Amount
LUCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.41
-0.03 (-2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners6.95%
Inst Owner Change97.52%
Ins Owners18.96%
Ins Owner Change-0.89%
Market Cap7.54M
Revenue(TTM)2.39M
Net Income(TTM)-7.85M
Analysts82.86
Price Target3.06 (117.02%)
Short Float %11.3%
Short Ratio0.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.97%
Min EPS beat(2)15.97%
Max EPS beat(2)23.97%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.87%
Min Revenue beat(2)-43.24%
Max Revenue beat(2)-34.5%
Revenue beat(4)0
Avg Revenue beat(4)-41.35%
Min Revenue beat(4)-55.39%
Max Revenue beat(4)-32.28%
Revenue beat(8)1
Avg Revenue beat(8)-18.57%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40%
PT rev (3m)-40%
EPS NQ rev (1m)10.42%
EPS NQ rev (3m)10.42%
EPS NY rev (1m)6.81%
EPS NY rev (3m)15.77%
Revenue NQ rev (1m)-65.71%
Revenue NQ rev (3m)-65.71%
Revenue NY rev (1m)-27.5%
Revenue NY rev (3m)-27.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.74 | ||
| P/tB | 0.77 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.63
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.45
BVpS1.92
TBVpS1.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.22% | ||
| ROE | -76.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.83% | ||
| FCFM | N/A |
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 89.89% | ||
| Cap/Sales | 5.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.98 | ||
| Quick Ratio | 10.13 | ||
| Altman-Z | -0.08 |
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)402.41%
Cap/Depr(5y)N/A
Cap/Sales(3y)23.82%
Cap/Sales(5y)37.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.62%
EPS Next Y71.92%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)53.21%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%163.46%
Revenue Next Year52.63%
Revenue Next 2Y117.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.43%
OCF growth 3YN/A
OCF growth 5YN/A
INNOVATIVE EYEWEAR INC / LUCY FAQ
Can you provide the ChartMill fundamental rating for INNOVATIVE EYEWEAR INC?
ChartMill assigns a fundamental rating of 4 / 10 to LUCY.
What is the valuation status for LUCY stock?
ChartMill assigns a valuation rating of 1 / 10 to INNOVATIVE EYEWEAR INC (LUCY). This can be considered as Overvalued.
What is the profitability of LUCY stock?
INNOVATIVE EYEWEAR INC (LUCY) has a profitability rating of 0 / 10.
What is the financial health of INNOVATIVE EYEWEAR INC (LUCY) stock?
The financial health rating of INNOVATIVE EYEWEAR INC (LUCY) is 7 / 10.
What is the earnings growth outlook for INNOVATIVE EYEWEAR INC?
The Earnings per Share (EPS) of INNOVATIVE EYEWEAR INC (LUCY) is expected to grow by 71.92% in the next year.